For Press Inquiries, please contact:

David Pitts
Argot Partners
(212) 600-1902


Tivozanib: An oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)

TIVO-3: A Phase 3 Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC

TiNivo: A Phase 1/2 trial in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab) in RCC